نتائج البحث - Hope Qamoos

  • يعرض 1 - 4 نتائج من 4
تنقيح النتائج
  1. 1
    PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

    PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS)... حسب Francesca Palandri, Stefanie Gröpper, Michaël Loschi, Marcelo Bellesso, Sebastian Grosicki, Pilar Giraldo, Claire Harrison, Tracy Clevenger, Nikki Stuart, Hope Qamoos, Gregory Vosganian, Wayne P. Rothbaum, Srđan Verstovšek, Pankit Vachhani

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

    The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas حسب Steven G. DuBois, Theodore W. Laetsch, Noah Federman, Brian Turpin, Catherine M. Albert, Ramamoorthy Nagasubramanian, Megan E. Anderson, Jessica L. Davis, Hope Qamoos, Mark Reynolds, Scott Cruickshank, Michael C. Cox, Douglas S. Hawkins, Leo Mascarenhas, Alberto S. Pappo

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)

    P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PL... حسب Michaël Loschi, László Rejtő, Hun Chuah, Marianna Caramella, Jesus Hernández Rivas, Paolo Sportoletti, Viviane Dubruille, Marcelo Bellesso, Stefanie Gröpper, Carl C. Crodel, Hope Qamoos, Ashley Socotch, Zhuying Huang, Sarah Wall, Jesse McGreivy, Wayne P. Rothbaum, Srđan Verstovšek, Francesca Palandri

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

    Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study حسب Carrie L. Kitko, Mukta Arora, Zachariah DeFilipp, Mohammad Abu Zaid, Antonio Di Stasi, Vedran Radojčić, Courtney B. Betts, Lisa M. Coussens, Michael L. Meyers, Hope Qamoos, Peter Ordentlich, Vinit Kumar, Christine Quaranto, Aaron Schmitt, Yu Gu, Bruce R. Blazar, Trent Wang, Amandeep Salhotra, Iskra Pusic, Madan Jagasia, Stephanie J. Lee

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: